Immune modulation in gastrointestinal disorders: New opportunities for therapeutic peptides?

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 6, 2008, Pages 741-748

  de Jonge, Wouter J ^a   Greaves, David R ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Anti inflammatory drug; Chemerin; G protein coupled receptor; Ghrelin; Immunomodulation; Inflammatory bowel disease; Peripheral opioid antagonist; Postoperative ileus; Vasoactive intestinal peptide

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; CD59 ANTIGEN; CORTISTATIN; FEDOTOZINE; G PROTEIN COUPLED RECEPTOR; GHRELIN; LIPOXIN; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NEUROPEPTIDE; OMEGA 3 FATTY ACID; OPIATE RECEPTOR; PEPTIDE HORMONE; RC 1139; RESOLVIN E1; SOMATOSTATIN; TUMOR NECROSIS FACTOR ANTIBODY; TZP 101; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; CHEMOKINE RECEPTOR; CMKLR1 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR;

ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DRUG TARGETING; ENTERITIS; ENTEROPATHY; GASTROINTESTINAL DISEASE; HORMONE RECEPTOR INTERACTION; HUMAN; ILEUS; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INTESTINE FUNCTION; NONHUMAN; PANCREATITIS; PERITONITIS; POSTOPERATIVE COMPLICATION; PROTEIN SECRETION; REPERFUSION INJURY; SEPSIS; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH PARESIS; ULCERATIVE COLITIS; HOMEOSTASIS; IMMUNOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

GASTROINTESTINAL DISEASES; HOMEOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; NEUROPEPTIDES; RECEPTORS, CHEMOKINE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 61549103125     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.6.741     Document Type: Article

References (61)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152), 427-434 (2007).
2. Izcue A, Coombes JL, Powrie F. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol. Rev. 212, 256-271 (2006).
3. Elson CO, Cong Y, Lorenz R, Weaver CT. New developments in experimental models of inflammatory bowel disease. Curr. Opin. Gastroenterol. 20(4), 360-367 (2004).
4. Greenwood-Van MB. Emerging drugs for postoperative ileus. Expert. Opin. Emerg. Drugs 12(4), 619-626 (2007).
5. Prasad M, Matthews JB. Deflating postoperative ileus. Gastroenterology 117(2), 489-492 (1999).
6. Bauer AJ, Boeckxstaens GE. Mechanisms of postoperative ileus. Neurogastroenterol. Motil. 16(Suppl. 2), 54-60 (2004).
7. de Jonge WJ, van den Wijngaard RM, The FO et al. Postoperative ileus is maintained by intestinal immune infiltrates that activate inhibitory neural pathways in mice. Gastroenterology 125(4), 1137-1147 (2003).
8. de Jonge WJ, The FO, van der CD et al. Mast-cell degranulation during abdominal surgery initiates postoperative ileus in mice. Gastroenterology 127(2), 535-545 (2004).
9. The FO, de Jonge WJ, Bennink RJ, van den Wijngaard RM, Boeckxstaens GE. The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice. Br. J. Pharmacol. 146(2), 252-258 (2005).
10. The FO, Bennink RJ, Ankum WM et al. Intestinal handling-induced mast cell activation and inflammation in human postoperative ileus. Gut 57(1), 33-40 (2008).
11. Thompson J. Pathogenesis and prevention of adhesion formation. Dig. Surg. 15(2), 153-157 (1998).
12. Vural B, Canturk NZ, Esen N et al. The role of neutrophils in the formation of peritoneal adhesions. Hum. Reprod. 14(1), 49-54 (1999).
13. Pol O, Alameda F, Puig MM. Inflammation enhances μ-opioid receptor transcription and expression in mice intestine. Mol. Pharmacol. 60(5), 894-899 (2001).
14. Stein C, Schafer M, Hassan AH. Peripheral opioid receptors. Ann. Med. 27(2), 219-221 (1995).
15. Roy S, Barke RA, Loh HH. μ-opioid receptor-knockout mice: role of μ-opioid receptor in morphine mediated immune functions. Brain Res. Mol. Brain Res. 61(1-2), 190-194 (1998).
16. Schiller PW. Opioid peptide-derived analgesics. AAPS J. 7(3), E560-E565 (2005).
17. Taguchi A, Sharma N, Saleem RM et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N. Engl. J. Med. 345(13), 935-940 (2001).
18. De Winter BY, Boeckxstaens GE, De Man JG, Moreels TG, Herman AG, Pelckmans PA. Effects of μ- and κ-opioid receptors on postoperative ileus in rats. Eur. J. Pharmacol. 339(1), 63-67 (1997).
19. Bonaz B, Riviere PJ, Sinniger V et al. Fedotozine, a κ-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterol. Motil. 12(2), 135-147 (2000).
20. Azodo IA, Ehrenpreis ED. Alvimopan (Adolor/GlaxoSmithKline). Curr. Opin. Investig. Drugs 3(10), 1496-1501 (2002).
21. Delaney CP, Wolff BG, Viscusi ER et al. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of Phase III studies. Ann. Surg. 245(3), 355-363 (2007).
22. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762), 656-660 (1999).
23. Nakazato M, Murakami N, Date Y et al. A role for ghrelin in the central regulation of feeding. Nature 409(6817), 194-198 (2001).
24. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 407(6806), 908-913 (2000).
25. Broglio F, Papotti M, Muccioli G, Ghigo E. Brain-gut communication: cortistatin, somatostatin and ghrelin. Trends Endocrinol. Metab. 18(6), 246-251 (2007).
26. Dembinski A, Warzecha Z, Ceranowicz P et al. Ghrelin attenuates the development of acute pancreatitis in rat. J. Physiol. Pharmacol. 54(4), 561-573 (2003).
27. Gonzalez-Rey E, Chorny A, Del Moral RG, Varela N, Delgado M. Therapeutic effect of cortistatin on experimental arthritis by downregulating inflammatory and Th1 responses. Ann. Rheum. Dis. 66(5), 582-588 (2007).
28. Dembinski A, Warzecha Z, Ceranowicz P et al. Role of growth hormone and insulin-like growth factor-1 in the protective effect of ghrelin in ischemia/reperfusion-induced acute pancreatitis. Growth Horm. IGF Res. 16(5-6), 348-356 (2006).
29. Chorny A, Anderson P, Gonzalez-Rey E, Delgado M. Ghrelin protects against experimental sepsis by inhibiting high-mobility group box 1 release and by killing bacteria. J. Immunol. 180(12), 8369-8377 (2008).
30. Gonzalez-Rey E, Chorny A, Delgado M. Therapeutic action of ghrelin in a mouse model of colitis. Gastroenterology 130(6), 1707-1720 (2006).
31. Tracey KJ. The inflammatory reflex. Nature 420(6917), 853-859 (2002).
32. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M. Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J. Exp. Med. 203(3), 563-571 (2006).
33. Peeters TL. Central and peripheral mechanisms by which ghrelin regulates gut motility. J. Physiol. Pharmacol. 54 (Suppl. 4), 95-103 (2003).
34. De Winter BY, De Man JG, Seerden TC et al. Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. Neurogastroenterol. Motil. 16(4), 439-446 (2004).
35. Venkova K, Fraser G, Hoveyda HR, Greenwood-Van MB. Prokinetic effects of a new ghrelin receptor agonist TZP-101 ifl a rat model of postoperative ileus. Dig. Dis. Sci. 52(9), 2241-2248 (2007).
36. Lasseter KC, Shaughnessy L, Cummings D et al. Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a Phase I, first-in-human study. J. Clin. Pharmacol. 48(2), 193-202 (2008).
37. The FO, Boeckxstaens GE, Snoek SA et al. Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology 133(4), 1219-1228 (2007).
38. Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm. Bowel. Dis. 13(7), 918-932 (2007).
39. Newman R, Cuan N, Hampartzoumian T, Connor SJ, Lloyd AR, Grimm MC. Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin. Exp. Immunol. 139(3), 411-420 (2005).
40. Kimata H, Fujimoto M. Induction of IgA1 and IgA2 production in immature human fetal B cells and pre-B cells by vasoactive intestinal peptide. Blood 85(8), 2098-2104 (1995).
41. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107(9), 3632-3638 (2006).
42. Bayguinov O, Keef KD, Hagen B, Sanders KM. Parallel pathways mediate inhibitory effects of vasoactive intestinal polypeptide and nitric oxide in canine fundus. Br. J. Pharmacol. 126(7), 1543-1552 (1999).
43. D'Amato M, Curro D, Montuschi P, Ciabattoni G, Ragazzoni E, Lefebvre RA. Release of vasoactive intestinal polypeptide from the rat gastric fundus. Br. J. Pharmacol. 105(3), 691-695 (1992).
44. Boeckxstaens GE, Hollmann M, Heisterkamp SH et al. Evidence for VIP(1)/PACAP receptors in the afferent pathway mediating surgery-induced fundic relaxation in the rat. Br. J. Pharmacol. 131(4), 705-710 (2000).
45. Takahashi T, Owyang C. Vagal control of nitric oxide and vasoactive intestinal polypeptide release in the regulation of gastric relaxation in rat. J. Physiol. (Lond.) 484(Pt 2), 481-492 (1995).
46. de Jonge WJ, van der Zanden EP, The FO et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6(8), 844-851 (2005).
47. Surrenti C, Renzi D, Garcea MR, Surrenti E, Salvadori G. Colonic vasoactive intestinal polypeptide in ulcerative colitis. J. Physiol. (Paris) 87(5), 307-311 (1993).
48. Tuncel N, Tore F, Sahinturk V, Ak D, Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 21(1), 81-89 (2000).
49. Ottosson A, Edvinsson L. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17(3), 166-174 (1997).
50. Bannenberg G, Moussignac RL, Gronert K et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br. J. Pharmacol. 143(1), 43-52 (2004).
51. Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174(7), 4345-4355 (2005).
52. Arita M, Yoshida M, Hong S et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl Acad. Sci. USA 102(21), 7671-7676 (2005).
53. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349-361 (2008).
54. Chiang N, Serhan CN, Dahlen SE et al. The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol. Rev. 58(3), 463-487 (2006).
55. Perretti M. The annexin 1 receptor(s): is the plot unravelling? Trends Pharmacol. Sci. 24(11), 574-579 (2003).
56. Cash JL, Hart R, Russ A et al. Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205(4), 767-775 (2008).
57. Zabel BA, Ohyama T, Zuniga L et al. Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-β and TLR ligands. Exp. Hematol. 34(8), 1106-1114 (2006).
58. Wittamer V, Franssen JD, Vulcano M et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198(7), 977-985 (2003).
59. Yoshimura T, Oppenheim JJ. Chemerin reveals its chimeric nature. J. Exp. Med. 205(10), 2187-2190 (2008).
60. Wehner S, Behrendt FF, Lyutenski BN et al. Inhibition of macrophage function prevents intestinal inflammation and postoperative ileus in rodents. Gut 56(2), 176-185 (2007).
61. Kehlet H. Postoperative ileus - an update on preventive techniques. Nat. Clin. Pract. Gastroenterol. Hepatol. 5(10), 552-558 (2008).